Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
59,498,729
-
Share change
-
+1,860,663
-
Total reported value
-
$3,213,541,420
-
Put/Call ratio
-
107%
-
Price per share
-
$54.01
-
Number of holders
-
442
-
Value change
-
+$82,310,330
-
Number of buys
-
194
-
Number of sells
-
197
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2024
As of 30 Jun 2024,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
442 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,498,729 shares.
The largest 10 holders included
Capital International Investors, ARK Investment Management LLC, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., BlackRock Inc., T. Rowe Price Investment Management, Inc., STATE STREET CORP, FMR LLC, VANGUARD GROUP INC, and NEA Management Company, LLC.
This page lists
440
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.